Jim Simons Silverback Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Silverback Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 15,800 shares of SBTX stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,800

Previous 124,100 87.27%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	N/A	-108,300 Reduced 87.27%	15,800 $0
Q2 2024 Aug 09, 2024	BUY	N/A	111,500 Added 884.92%	124,100 $0
Q1 2024 May 13, 2024	SELL	N/A	-39,400 Reduced 75.77%	12,600 $129,000
Q4 2023 Feb 13, 2024	SELL	N/A	-85,700 Reduced 62.24%	52,000 $285,000
Q3 2023 Nov 14, 2023	SELL	N/A	-166,600 Reduced 54.75%	137,700 $521,000
Q2 2023 Aug 11, 2023	SELL	N/A	-26,300 Reduced 7.96%	304,300 $2.04 Million
Q1 2023 May 12, 2023	BUY	N/A	19,600 Added 6.3%	330,600 $2.15 Million
Q4 2022 Feb 13, 2023	SELL	$0.0 - $6.07 $0 - $20,638	-3,400 Reduced 1.08%	311,000 $2.65 Million
Q3 2022 Nov 14, 2022	SELL	$3.91 - $5.52 $918,455 - $1.3 Million	-234,899 Reduced 42.76%	314,400 $1.66 Million
Q2 2022 Aug 12, 2022	SELL	$2.9 - $4.44 $351,604 - $538,318	-121,243 Reduced 18.08%	549,299 $2.33 Million
Q1 2022 May 13, 2022	BUY	$3.51 - $6.74 $1.06 Million - $2.04 Million	302,542 Added 82.21%	670,542 $2.35 Million
Q4 2021 Feb 11, 2022	BUY	$6.03 - $11.67 $1.52 Million - $2.93 Million	251,400 Added 215.61%	368,000 $2.45 Million
Q3 2021 Nov 12, 2021	BUY	$9.98 - $35.22 $1.16 Million - $4.11 Million	116,600 New	116,600 $1.16 Million

Others Institutions Holding SBTX

# of Institutions

163

Shares Held

62.7M

Call Options Held

872K

Put Options Held

589K

View Full List

About Silverback Therapeutics, Inc.

Ticker SBTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,473,800
Description
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...

More about SBTX

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account